Brief: Nurix Therapeutics Receives U.S. FDA Fast Track Designation For Nx-5948
19/12/2024 13:00
Dec 19 (Reuters) - Nurix Therapeutics Inc NRIX.O :
* NURIX THERAPEUTICS RECEIVES U.S. FDA FAST TRACK
DESIGNATION FOR
NX-5948 FOR THE TREATMENT OF RELAPSED OR REFRACTORY
WALDENSTROM’S MACROGLOBULINEMIA
* NURIX THERAPEUTICS : ANTICIPATE SHARING ADDITIONAL
CLINICAL DATA
ABOUT ONGOING PHASE 1B EXPANSION COHORT IN 2025
Source text: ID:nGNX2tWLsG
Further company coverage: NRIX.O
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis